The Use of Anti-Müllerian Hormone in Predicting Menstrual Response after Weight Loss in Overweight Women with Polycystic Ovary Syndrome

Moran, Lisa J.; Noakes, Manny; Clifton, Peter M.; Norman, Robert J.

doi:10.1210/jc.2007-1188

Cited by 54 publications

(47 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, AMH can be used for predicting menstrual response in overweight PCOS patients after weight loss. The patients with low AMH baseline level get more chances to be improved menstrual response [20]. However, another study shows that a 20-week weight loss intervention has no effect on AMH secretion [29].…”

Section: Discussionmentioning

confidence: 98%

Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism

Li¹,

Ma²,

Chen³

et al. 2012

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The aim of this study is to compare the secretory profiles and diagnostic power of anti-Mullerian hormone (AMH) for the PCOS patient with and without hyperandrogenism. Methods One hundred and thirty-one PCOS patients with oligomenorrhea or amenorrhea were recruited into the study. Sixty-two and sixty-nine patients had and did not have hyperandrogenism (HA+) hyperandrogenism (HA−), respectively. Sera were collected for determining the levels of AMH, basal sexual hormones, glucose and lipid metabolic indicators. Results The AMH serum levels of PCOS patients were significantly higher than the control group, with the highest AMH serum level in the HA+ group. The cut-off value for predicting PCOS patients of all types was 3.92 ng/mL, with a sensitivity of 65 %, and specificity of 62 %. The cut-off value for predicting PCOS patients in the HA+ group was 4.23 ng/mL, with a sensitivity of 82 %, and specificity of 64 %. The cut-off value for predicting PCOS patients in the HA− group was 3.76 ng/mL, with a sensitivity of 64 %, and specificity of 62 %. In the HA+ group, AMH was negatively associated with FSH and positively associated with LH. In the HA− group, AMH was negatively associated with HDL and positively associated with BMI, fasting glucose and LDL.Conclusions AMH is only suitable for predicting the PCOS patients with hyperandrogenism. The diagnostic power of AMH is limited when used to predict patients without hyperandrogenism. It reflects the differences in pathophysiology and severity of disrupted folliculogenesis between the two subtypes.

show abstract

Section: Discussionmentioning

confidence: 98%

Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism

Li¹,

Ma²,

Chen³

et al. 2012

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…In addition, measurement of serum AMH levels may also be used as an indicator of PCOS patients’ response to therapeutic approaches [33], including ovarian response to clomiphene citrate [34], evaluation after treatment with insulin sensitizers [24], and monitoring after laparoscopic ovarian drilling [26]. …”

Section: Discussionmentioning

confidence: 99%

Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients

Wiweko

Maidarti

Priangga

et al. 2014

J Assist Reprod Genet

View full text Add to dashboard Cite

PurposeTo determine whether the measurement of serum AMH can be used to diagnose PCOS and as a tool to predict the prognosis of PCOS.MethodsThis is a case–control study. Women of reproductive age (18–35 years) were recruited consecutively at a tertiary academic hospital during the period of March 2009–October 2011 and were divided into case (PCOS patients defined by the Rotterdam criteria) and control groups (non-PCOS patients). Menstrual history, clinical manifestations of hyperandrogenism, ovarian ultrasound assessments, and the levels of AMH, LH, FSH, and estradiol were collected.ResultsSeventy-one cases and 71 controls were recruited. AMH serum levels were significantly higher in PCOS patients than in controls. The Area Under the Curve (AUC) of the serum AMH assay in PCOS patients reached a value of 0.870. With a cut-off value of 4.45 ng/ml, the serum AMH level had a sensitivity of 76.1 % and a specificity of 74.6 %. The most common phenotypes of PCOS in this study were anovulation and polycystic ovary (63.4 %). However, the mean level of AMH was highest in the phenotypes of anovulation, polycystic ovaries and hyperandrogenism (11.1 ng/ml).ConclusionsIn Indonesian women, AMH can be used as an alternative diagnostic criteria for PCOS patients with a cut-off value of 4.45 ng/ml. AMH value rise when hyperandrogenism is present therefore serum AMH levels also reflect the phenotype of PCOS. However, these findings must be confirmed with larger clinical studies.

show abstract

“…82 In contrast, the menstrual cycles of women who had higher AMH levels before losing weight did not improve. The authors recommended AMH measurement in overweight and obese women prior to weight loss program implementation as a prognostic tool of the menstrual cycle improvement.…”

Section: Amh and Obesitymentioning

confidence: 94%

The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology

Karkanaki¹,

Vosnakis²,

Panidis³

2011

View full text Add to dashboard Cite

Anti-Müllerian hormone (AMH) is a homodimeric glycoprotein, a member of the transforming growth factor-β superfamily. Over the last decade, a large number of studies examining the multiple roles of AMH have been published. AMH levels accurately reflect the ovarian follicular reserve and could, therefore, be considered as an extremely sensitive marker of ovarian aging and a valuable tool in the diagnosis and the recognition of recurrence of granulosa cell tumors. Furthermore, AMH evaluation is of clinical importance in predicting the success of in vitro fertilization (IVF). Additionally, AMH could be a surrogate diagnostic marker of polycystic ovary syndrome in cases in which ultrasonographic examination is not possible. This article is a review of the clinical usefulness of AMH evaluation in the fields of gynecological endocrinology, menopause, gynecological oncology and assisted reproduction. Special reference is made to the possible implications of AMH in the pathogenesis of polycystic ovary syndrome and the relationship between AMH and obesity.

show abstract

The Use of Anti-Müllerian Hormone in Predicting Menstrual Response after Weight Loss in Overweight Women with Polycystic Ovary Syndrome

Cited by 54 publications

References 61 publications

Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism

Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism

Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients

The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology

Contact Info

Product

Resources

About